| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | 0 |
Sells | $1,176,157 | 13 | 100 |
| Muller Lorenz | Chief Commercial Officer | 0 | $0 | 2 | $145,851 | $-145,851 |
| Bharucha David | Chief Medical Officer | 0 | $0 | 2 | $158,209 | $-158,209 |
| Hasija Amit | CFO & EVP of Corp. Development | 0 | $0 | 2 | $158,209 | $-158,209 |
| Nelson Jeffrey Edward | Chief Operating Officer | 0 | $0 | 2 | $158,209 | $-158,209 |
| Oliveto Joseph | President and CEO | 0 | $0 | 5 | $555,680 | $-555,680 |
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.
Over the last 12 months, insiders at Milestone Pharmaceuticals Inc. have bought $0 and sold $1.18M worth of Milestone Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Milestone Pharmaceuticals Inc. have bought $6.96M and sold $7.37M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,000 shares for transaction amount of $32,830 was made by Bharucha David (Chief Medical Officer) on 2022‑12‑05.
| 2026-04-16 | Sale | Oliveto Joseph | President and CEO | 36,500 0.046% | $2.26 | $82,490 | -38.76% | |
| 2026-01-26 | Sale | Oliveto Joseph | President and CEO | 34,523 0.0403% | $1.93 | $66,629 | -29.38% | |
| 2026-01-26 | Sale | Muller Lorenz | Chief Commercial Officer | 11,180 0.0131% | $1.93 | $21,577 | -29.38% | |
| 2026-01-26 | Sale | Bharucha David | Chief Medical Officer | 12,245 0.0143% | $1.93 | $23,633 | -29.38% | |
| 2026-01-26 | Sale | Hasija Amit | CFO & EVP of Corp. Development | 12,245 0.0143% | $1.93 | $23,633 | -29.38% | |
| 2026-01-26 | Sale | Nelson Jeffrey Edward | Chief Operating Officer | 12,245 0.0143% | $1.93 | $23,633 | -29.38% | |
| 2026-01-08 | Sale | Oliveto Joseph | President and CEO | 43,000 0.0519% | $2.25 | $96,750 | -34.70% | |
| 2026-01-07 | Sale | Oliveto Joseph | President and CEO | 500 0.0006% | $2.25 | $1,125 | -33.26% | |
| 2025-12-15 | Sale | Oliveto Joseph | President and CEO | 133,054 0.1549% | $2.32 | $308,685 | -32.34% | |
| 2025-12-15 | Sale | Muller Lorenz | Chief Commercial Officer | 53,566 0.0624% | $2.32 | $124,273 | -32.34% | |
| 2025-12-15 | Sale | Bharucha David | Chief Medical Officer | 58,007 0.0675% | $2.32 | $134,576 | -32.34% | |
| 2025-12-15 | Sale | Hasija Amit | CFO & EVP of Corp. Development | 58,007 0.0675% | $2.32 | $134,576 | -32.34% | |
| 2025-12-15 | Sale | Nelson Jeffrey Edward | Chief Operating Officer | 58,007 0.0675% | $2.32 | $134,576 | -32.34% | |
| 2022-12-05 | Bharucha David | Chief Medical Officer | 7,000 0.0162% | $4.69 | $32,830 | -27.58% | ||
| 2022-12-01 | Bharucha David | Chief Medical Officer | 3,000 0.007% | $4.86 | $14,580 | -29.01% | ||
| 2022-10-21 | Liebert Debra K. | director | 4,000 0.0096% | $5.26 | $21,040 | -28.77% | ||
| 2022-10-20 | Pasternak Richard C | director | 10,000 0.0232% | $5.20 | $52,000 | -30.21% | ||
| 2022-10-20 | Liebert Debra K. | director | 10,000 0.0236% | $5.29 | $52,900 | -30.21% | ||
| 2022-10-19 | Wills Robert James | director | 15,000 0.0349% | $4.93 | $73,950 | -26.41% | ||
| 2022-10-19 | TOMSICEK MICHAEL JOHN | director | 15,000 0.0376% | $5.32 | $79,800 | -26.41% |
| Oliveto Joseph | President and CEO | 446244 0.3584% | $535,492.80 | 0 | 5 | |
| Muller Lorenz | Chief Commercial Officer | 205406 0.165% | $246,487.20 | 0 | 2 | |
| Bharucha David | Chief Medical Officer | 113181 0.0909% | $135,817.20 | 2 | 2 | <0.0001% |
| Hasija Amit | CFO & EVP of Corp. Development | 99848 0.0802% | $119,817.60 | 0 | 2 | |
| Nelson Jeffrey Edward | Chief Operating Officer | 49848 0.04% | $59,817.60 | 0 | 2 | |
| RTW INVESTMENTS, LP | 10 percent owner | 4315102 3.466% | $5.18M | 13 | 0 | |
| WONG RODERICK | 4315102 3.466% | $5.18M | 1 | 1 | <0.0001% | |
| Novo Holdings A/S | 10 percent owner | 2434470 1.9554% | $2.92M | 1 | 1 | |
| BDC CAPITAL INC. | 10 percent owner | 2388088 1.9182% | $2.87M | 1 | 0 | |
| FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC | 10 percent owner | 2254920 1.8112% | $2.71M | 1 | 2 | |
| TRUEX PAUL F | 81780 0.0657% | $98,136.00 | 1 | 0 | <0.0001% | |
| TOMSICEK MICHAEL JOHN | director | 15000 0.012% | $18,000.00 | 1 | 0 | <0.0001% |
| Wills Robert James | director | 15000 0.012% | $18,000.00 | 1 | 0 | <0.0001% |
| Pasternak Richard C | director | 10000 0.008% | $12,000.00 | 1 | 0 | <0.0001% |
| Liebert Debra K. | director | 4000 0.0032% | $4,800.00 | 2 | 0 | <0.0001% |
$15,998,851 | 75 | 1.70% | $157.04M | |
$66,137,559 | 49 | 6.29% | $133.36M | |
$19,086,607 | 44 | 0.14% | $174.98M | |
$161,692,548 | 20 | 18.00% | $148.25M | |
$762,249 | 19 | 3.16% | $178.58M | |
$33,128,160 | 18 | -13.64% | $146.77M | |
$207,086 | 15 | 14.15% | $130.44M | |
$277,862 | 15 | 59.79% | $147.87M | |
$8,069,667 | 13 | -13.57% | $121.92M | |
$13,486,672 | 11 | 82.26% | $124.63M | |
Milestone Pharmaceuticals Inc. (MIST) | $13,919,584 | 9 | -30.43% | $149.4M |
$344,394 | 8 | -22.26% | $155.71M | |
$36,049,976 | 5 | -3.82% | $170.19M | |
$149,778 | 4 | -45.16% | $138.16M | |
$32,007,657 | 4 | -45.65% | $182.66M | |
$193,101 | 3 | -25.20% | $151.53M | |
$2,857,000 | 2 | -5.23% | $172.98M | |
$8,997,728 | 2 | -11.16% | $159.44M | |
$2,590,000 | 1 | 37.38% | $144.98M |
| Increased Positions | 49 | +81.67% | 7M | +21.64% |
| Decreased Positions | 19 | -31.67% | 15M | -42.83% |
| New Positions | 28 | New | 3M | New |
| Sold Out Positions | 10 | Sold Out | 6M | Sold Out |
| Total Postitions | 90 | +50% | 27M | -21.19% |
| Adage Capital Partners Gp, L.L.C. | $14,301.00 | 8.21% | 6.98M | +7M | New | 2025-09-30 |
| Propel Bio Management, Llc | $10,506.00 | 6.03% | 5.12M | +3M | +186.06% | 2025-09-30 |
| Orbimed Advisors Llc | $6,605.00 | 3.79% | 3.22M | +3M | New | 2025-09-30 |
| Morgan Stanley | $6,087.00 | 3.49% | 2.97M | +2M | +261.9% | 2025-09-30 |
| Simplify Asset Management Inc. | $5,808.00 | 3.33% | 2.83M | +2M | +186.16% | 2025-09-30 |
| Rtw Investments, Lp | $5,138.00 | 2.95% | 2.51M | 0 | 0% | 2025-09-30 |
| Pathstone Holdings, Llc | $2,050.00 | 1.18% | 1M | +1M | New | 2025-09-30 |
| Sphera Funds Management Ltd. | $1,681.00 | 0.97% | 820,000 | +820,000 | New | 2025-09-30 |
| Toronto Dominion Bank | $1,538.00 | 0.88% | 750,000 | 0 | 0% | 2025-09-30 |
| Affinity Asset Advisors, Llc | $1,367.00 | 0.78% | 666,666 | +666,666 | New | 2025-09-30 |